Morphic-Brand-NoTMLogo-RGB-082321-01.png
Morphic Presents Preclinical Data from αvβ8 Integrin Program at the SITC Annual Meeting
November 15, 2021 09:05 ET | Morphic Therapeutic
αvβ8 inhibition demonstrates efficacy in a cancer model refractory to radiation and checkpoint inhibition Data provide increased rationale to explore integrin inhibition as a component in combination...
Nurix.png
Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors
November 12, 2021 07:09 ET | Nurix Therapeutics, Inc.
Food and Drug Administration clears DeTIL-0255 to initiate Phase 1 clinical trial Phase 1 clinical trial initiation anticipated by year-end 2021 SAN FRANCISCO, Nov. 12, 2021 (GLOBE NEWSWIRE) --...
Nurix.png
Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference
November 12, 2021 07:07 ET | Nurix Therapeutics, Inc.
DeTIL-0255 is a drug-enhanced investigational new cell therapy product candidate with potentially superior T cell properties compared to conventional TIL Michael T. Lotze, Nurix’s chief cellular...
Neoleukin.png
Neoleukin Therapeutics Presents NL-201 Preclinical Data at Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
November 12, 2021 07:05 ET | Neoleukin Therapeutics, Inc.
SEATTLE, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Adaptimmune logo Colour_white background_no strap.jpg
Translational Data at SITC 2021 from Adaptimmune’s Phase 1 SURPASS Trial Indicate Adding AKTi to Manufacturing May Contribute to Sustained Antitumor Activity of Next-gen SPEAR T-cells
November 12, 2021 07:00 ET | Adaptimmune Therapeutics plc
- Inhibition of AKT signaling during ex vivo T-cell expansion phase of manufacturing provides further proliferative potential and enhanced memory phenotype of next-gen SPEAR T-cells - - Data suggests...
Atyr_Logo.png
aTyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, ATYR2810, on Tumor Associated Macrophages at the Society for Immunotherapy of Cancer Annual Meeting
November 09, 2021 08:05 ET | aTyr Pharma, Inc.
 Findings provide key insights into ATYR2810’s potential mechanism of action, including ability to modulate key immune cells involved in tumor progression, metastasis and therapy resistance. Data...
Immunicum presenterar nya forskningsdata vid årsmötet för Society for Immunotherapy of Cancer (SITC)
November 09, 2021 08:00 ET | Immunicum AB
PressmeddelandeStockholm, Sverige, 9 november 2021Immunicum presenterar nya forskningsdata vid årsmötet för Society for Immunotherapy of Cancer (SITC)Immunicum AB (publ; IMMU.ST), ett bioteknikföretag...
Immunicum to Present New Research Data at The Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 09, 2021 08:00 ET | Immunicum AB
Press ReleaseStockholm, Sweden, November 9, 2021Immunicum to Present New Research Data at The Society for Immunotherapy of Cancer (SITC) Annual MeetingImmunicum AB (publ; IMMU.ST), a biopharmaceutical...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights
November 09, 2021 08:00 ET | Achilles Therapeutics PLC
- Oral Presentation at European Society for Gene and Cell Therapy (ESGCT) demonstrated ability to generate potent anti-cancer cell therapy candidates in multiple solid tumor types - - Society for...
AKOYA Bio - Logo - Standard Centered.png
Akoya Biosciences to Present Data at SITC 2021 Highlighting Novel Spatial Biology Applications
November 04, 2021 08:05 ET | Akoya Biosciences, Inc.
MARLBOROUGH, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company®, today announced that new data generated with its CODEX® and Phenoptics™...